Skip to content

Study · Observational study · n = 1,009 · 2025

8 results

Comprehensive analysis of real-world data on liraglutide treatment in patients with obesity: a multicenter national study.

Hepşen S, Haymana C, Cavnar Helvacı B, Durantaş H, Toros B, Çakmak R, Güven M, Demirci İ, Keskin L, Kıyıcı S, Şahin Alak ZY, Sargın M and 38 more

Show all authors

Tamer G, Balcı D, Aydoğan Bİ, Or Koca A, Aydemir M, Tarkun İ, Köksal P, Oğuz A, Demir Önal E, Baldane S, Kızılgül M, Çakal E, Çakır B, Polat ŞB, Yetkin İ, Bozkırlı E, Karaahmetli G, Fakı S, Yaghji NI, Öge A, Özbaş B, Topsakal Ş, Fırat SN, Bostan H, Karagün B, Bakıner OS, Kargılı Çarlıoğlu A, Evren B, Uğur K, Kılınç F, Batman A, Çakmak Demir S, Yazıcı D, Deyneli O, Arslan M, Topaloğlu O, Kocatepe K, Karagözoğlu K

European journal of medical research10 Oct 2025Cited by 1 (Europe PMC)

PMID41074095 (opens in a new tab)PMCIDPMC12512425 (opens in a new tab)DOI10.1186/s40001-025-02836-5 (opens in a new tab)PepBankPUB-41074095
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanObservational studySafety outcome

    In adults with obesity treated with liraglutide in routine care, 48% had at least one side effect.

    In plain wordsIn adults with obesity treated with liraglutide in routine care, 48% had at least one side effect.

    Peptide
    Liraglutide
    Outcome
    Not applicablePatients with at least one side effect
    Study

    n = 1,009

    Outcome group
    Adverse events · Whole body
    Studied dose
    median 2.4 mg (IQR 1.8-3) · median 4 months (IQR 3-6)As given in this study (human).

    Measurements

    Patients with at least one side effect
    48%
    liraglutide cohort

    Source sentences

    Summary
    At least one side effect was observed in 48% of the patients, with nausea and vomiting being the most common.
    1 context sentence
    Summary · context
    This retrospective observational study analyzed data from 1009 patients across 38 endocrinology units from Türkiye.
  2. 02HumanObservational studySafety outcome

    In adults with obesity treated with liraglutide in routine care, nausea and vomiting were the most common side effects.

    In plain wordsIn adults with obesity treated with liraglutide in routine care, nausea and vomiting were the most common side effects.

    Peptide
    Liraglutide
    Outcome
    Not applicableNausea and vomiting
    Study

    n = 1,009

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    median 2.4 mg (IQR 1.8-3) · median 4 months (IQR 3-6)As given in this study (human).

    Source sentences

    Summary
    At least one side effect was observed in 48% of the patients, with nausea and vomiting being the most common.
    1 context sentence
    Summary · context
    This retrospective observational study analyzed data from 1009 patients across 38 endocrinology units from Türkiye.
  3. 03HumanObservational studyOther

    In adults with obesity treated with liraglutide in routine care, the cost of the medication was the most frequent reason for stopping treatment (42.6%).

    In plain wordsIn adults with obesity treated with liraglutide in routine care, medication cost was the most common reason for stopping (42.6%).

    Peptide
    Liraglutide
    Outcome
    Not applicableMost frequent reason for discontinuation: cost of medication
    Study

    n = 1,009

    Outcome group
    Adverse events · Whole body
    Studied dose
    median 2.4 mg (IQR 1.8-3) · median 4 months (IQR 3-6)As given in this study (human).

    Measurements

    Discontinuation because of cost
    42.6%
    liraglutide cohort

    Source sentences

    Summary
    The most frequent reason for discontinuing treatment was the cost of the medication (42.6%).
    1 context sentence
    Summary · context
    This retrospective observational study analyzed data from 1009 patients across 38 endocrinology units from Türkiye.
  4. 04HumanObservational studyEfficacy outcome

    In adults with obesity treated with liraglutide in routine care, 76.4% reached a 5% weight loss target.

    In plain wordsIn adults with obesity treated with liraglutide in routine care, 76.4% lost at least 5% of their weight.

    Peptide
    Liraglutide
    Outcome
    Not applicablePatients reaching 5% weight loss
    Study

    n = 1,009

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    median 2.4 mg (IQR 1.8-3) · median 4 months (IQR 3-6)As given in this study (human).

    Measurements

    Patients reaching 5% weight loss
    76.4%
    entire cohort

    Source sentences

    Summary
    Among the entire cohort, 76.4% and 40.9% of patients achieved a 5% and 10% weight loss target, respectively.
    1 context sentence
    Summary · context
    This retrospective observational study analyzed data from 1009 patients across 38 endocrinology units from Türkiye.
  5. 05HumanObservational studyEfficacy outcome

    In adults with obesity treated with liraglutide in routine care, 40.9% reached a 10% weight loss target.

    In plain wordsIn adults with obesity treated with liraglutide in routine care, 40.9% lost at least 10% of their weight.

    Peptide
    Liraglutide
    Outcome
    Not applicablePatients reaching 10% weight loss
    Study

    n = 1,009

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    median 2.4 mg (IQR 1.8-3) · median 4 months (IQR 3-6)As given in this study (human).

    Measurements

    Patients reaching 10% weight loss
    40.9%
    entire cohort

    Source sentences

    Summary
    Among the entire cohort, 76.4% and 40.9% of patients achieved a 5% and 10% weight loss target, respectively.
    1 context sentence
    Summary · context
    This retrospective observational study analyzed data from 1009 patients across 38 endocrinology units from Türkiye.
  6. 06HumanObservational studySafety outcome

    In adults with obesity treated with liraglutide in routine care, one patient developed pancreatitis on day 15 of treatment.

    In plain wordsIn adults with obesity treated with liraglutide in routine care, one patient developed pancreatitis on day 15 of treatment.

    Peptide
    Liraglutide
    Outcome
    Not applicablePancreatitis
    Study

    n: not reported in source

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    median 2.4 mg (IQR 1.8-3) · 15 daysAs given in this study (human).

    Source sentences

    Summary
    one patient who developed pancreatitis on the 15th day of treatment were excluded from the analyses of weight and laboratory changes.
    1 context sentence
    Summary · context
    This retrospective observational study analyzed data from 1009 patients across 38 endocrinology units from Türkiye.
  7. 07HumanObservational studyEfficacy outcome

    In adults with obesity treated with liraglutide in routine care, metabolic parameters fell significantly during treatment.

    In plain wordsIn adults with obesity treated with liraglutide in routine care, metabolic test values fell significantly during treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseMetabolic parameters during treatment
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    median 2.4 mg (IQR 1.8-3) · median 4 months (IQR 3-6)As given in this study (human).

    Source sentences

    Summary
    Significant reductions were observed in metabolic parameters during the treatment.
    1 context sentence
    Summary · context
    This retrospective observational study analyzed data from 1009 patients across 38 endocrinology units from Türkiye.
  8. 08HumanObservational studyOther

    In adults with obesity treated with liraglutide in routine care, longer treatment duration independently predicted reaching the 5% and 10% weight loss targets.

    In plain wordsIn adults with obesity treated with liraglutide in routine care, longer treatment was linked to a better chance of reaching weight loss targets.

    Peptide
    Liraglutide
    Outcome
    Not applicableTreatment duration as predictor of weight loss targets
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    median 2.4 mg (IQR 1.8-3) · median 4 months (IQR 3-6)As given in this study (human).

    Measurements

    Regression coefficient B
    0.315 B
    5% and 10% weight loss targets
    Regression coefficient B
    0.216 B
    10% weight loss

    Source sentences

    Summary
    The treatment duration was identified as an independent predictor for achieving 5% and 10% weight loss targets (B = 0.315, p < 0.001) and 10% weight loss (B = 0.216, p < 0.001).
    1 context sentence
    Summary · context
    This retrospective observational study analyzed data from 1009 patients across 38 endocrinology units from Türkiye.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.